|
Report Date : |
25.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
SYNERGY UNITED PHARMACHEM PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
G-1, Tiffany Building, Near Hiranandani Hospital, Hiranandani Estate, Ghodbander
Road, Thane – 400607, Maharashtra |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
01.09.2007 |
|
|
|
|
Com. Reg. No.: |
11-173718 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.15.000 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24239MH2007PTC173718 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
PNES21736B |
|
|
|
|
PAN No.: [Permanent Account No.] |
AALCS1621D |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer and Trader of Active Pharmaceutical Ingredient (API) and
Mercantile Exporter. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (46) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 130000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to be
usually correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office : |
G-1, Tiffany Building, Near Hiranandani Hospital, Hiranandani Estate,
Ghodbander Road, Thane – 400607, Maharashtra, India |
|
Tel. No.: |
91-22-40570602/03/04/05 |
|
Fax No.: |
91-22-40570609 |
|
E-Mail : |
|
|
Website : |
DIRECTORS
As on 30.09.2011
|
Name : |
Mr. Satish Prabhakar Nachane |
|
Designation : |
Director |
|
Address : |
1801, 18th Floor, Ixora Towers, Hiranandani
Meadows, Gladys- Alwaris Road, Off
Pokharan-2 Road, Thane - 400607, Maharashtra, India |
|
Date of Birth/Age : |
08.04.1946 |
|
Date of Appointment : |
15.09.2007 |
|
DIN No.: |
00005520 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company
Status |
Defaulting
status |
|
1 |
L37060MH1984PLC055433 |
AARTI
DRUGS LIMITED |
Managing
director |
05-01-85 |
05-01-85 |
30-07-07 |
Active |
NO |
|
2 |
U24239MH2007PTC173718 |
SYNERGY
UNITED PHARMACHEM PRIVATE LIMITED |
Director |
15-09-07 |
15-09-07 |
- |
Active |
NO |
|
3 |
U24232UP1998PLC023074 |
AMIT
HETEROCHEM LABS INDIA LIMITED |
Director |
20-02-08 |
20-02-08 |
18-03-09 |
Active |
NO |
|
4 |
U24232RJ1995PTC009496 |
MITHILA
DRUGS PRIVATE LIMITED |
Director |
20-09-08 |
14-09-08 |
- |
Active |
NO |
|
5 |
U24100MH2009PTC189592 |
DANOPHARM
CHEMICALS PRIVATE LIMITED |
Additional
director |
03-09-09 |
03-09-09 |
- |
Active |
NO |
|
6 |
U72900MH2009PTC196437 |
SYNERGY
UNITED INFO-STIMULI PRIVATE LIMITED |
Director |
14-10-09 |
14-10-09 |
- |
Active |
NO |
|
Name : |
Mr. Mehul Satish Nachane |
|
Designation : |
Director |
|
Address : |
1801, 18th Floor, Ixora Towers, Hiranandani
Meadows, Gladys- Alwaris Road, Off
Pokharan-2 Road, Thane - 400607, Maharashtra, India |
|
Date of Birth/Age : |
16.07.1981 |
|
Date of Appointment : |
01.09.2007 |
|
DIN No.: |
01669975 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U24239MH2007PTC173718 |
SYNERGY
UNITED PHARMACHEM PRIVATE LIMITED |
Director |
01-09-07 |
01-09-07 |
Active |
NO |
|
2 |
U24100MH2009PTC189592 |
DANOPHARM
CHEMICALS PRIVATE LIMITED |
Additional
director |
03-09-09 |
03-09-09 |
Active |
NO |
|
3 |
U72900MH2009PTC196437 |
SYNERGY
UNITED INFO-STIMULI PRIVATE LIMITED |
Director |
14-10-09 |
14-10-09 |
Active |
NO |
|
Name : |
Mr. Ramesh Eknath Jadhav |
|
Designation : |
Director |
|
Address : |
501, 5th Floor, ‘B’ Wing, Anant Regency, Phase 1, Near Jain
Society, Kala Talao, Kalyan, (West), 421301, Maharashtra, India |
|
Date of Birth/Age : |
05.11.1970 |
|
Date of Appointment : |
10.11.2007 |
|
DIN No.: |
01984279 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U24239MH2007PTC173718 |
SYNERGY
UNITED PHARMACHEM PRIVATE LIMITED |
Director |
10-11-07 |
10-11-07 |
Active |
NO |
|
2 |
U24232RJ1995PTC009496 |
MITHILA
DRUGS PRIVATE LIMITED |
Director |
20-09-08 |
14-09-08 |
Active |
NO |
|
3 |
U24100MH2009PTC189592 |
DANOPHARM
CHEMICALS PRIVATE LIMITED |
Director |
16-03-10 |
16-03-10 |
Active |
NO |
|
Name : |
Mr. Sabu Daniel |
|
Designation : |
Director |
|
Address : |
501, building ‘E’, New Bramhad, Azad Nagar, Kolshet, Thane (West),
Thane – 400607, Maharashtra, India |
|
Date of Birth/Age : |
03.01.1960 |
|
Date of Appointment : |
15.01.2008 |
|
DIN No.: |
01984280 |
Other Directorship:
|
S.No. |
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
1 |
U24239MH2007PTC173718 |
SYNERGY
UNITED PHARMACHEM PRIVATE LIMITED |
Director |
15-01-08 |
15-01-08 |
Active |
NO |
|
2 |
U24232RJ1995PTC009496 |
MITHILA
DRUGS PRIVATE LIMITED |
Director |
20-09-08 |
14-09-08 |
Active |
NO |
|
3 |
U24100MH2009PTC189592 |
DANOPHARM
CHEMICALS PRIVATE LIMITED |
Director |
16-03-10 |
16-03-10 |
Active |
NO |
|
Name : |
Mr. Sadhana Satish Nachane |
|
Designation : |
Director |
|
Address : |
1801, 18th Floor, Ixora Towers, Hiranandani
Meadows, Gladys- Alwaris Road, Off
Pokharan-2 Road, Thane - 400607, Maharashtra, India |
|
Date of Birth/Age : |
03.11.1949 |
|
Date of Appointment : |
01.09.2007 |
|
DIN No.: |
01669985 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2011
|
Names of Shareholders |
|
No. of Shares |
|
|
|
|
|
Sat1sh P. Nachane |
|
510000 |
|
Sadhana S. Nachane |
|
510000 |
|
Mehul S. Nachane |
|
300000 |
|
Ramesh Eknath Jadhav |
|
30000 |
|
Pratibha Ramesh Jadhav |
|
30000 |
|
Pranali Ramesh Jadhav |
|
7500 |
|
Namrata Ramesh Jadhav |
|
7500 |
|
Sabu Daniel |
|
30000 |
|
Lalykutty Sabu Daniel |
|
22500 |
|
Teena Sabu |
|
11250 |
|
Neha Sabu |
|
11250 |
|
Supriya
Tamhane |
|
15000 |
|
Abhijit Tamhane |
|
15000 |
|
Total
|
|
1500000 |
As on 30.09.2011
Equity Share Break up (Percentage of Total Equity)
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Trader of Active Pharmaceutical Ingredient (API) and
Mercantile Exporter. |
|
|
|
|
Products : |
ATORVASTATIN ·
( R )-4-Cyano-3-hydroxybutyric acid ethylester (
ATS-5 ) ·
(4R-Cis)1,1,-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
( ATS-8) ·
(4R-Cis)1,1,-dimethylethyl-6-aminoethyl-2,2dimethyl-1,3-dioxane-4-acetate
( ATS-9) ·
4-Fluoro-a-{2-methyl-oxopropyl}-y-oxo-N,B-diphenylbenzene
butanemide (M-4) ·
(4R-Cis)-1,1-dimethylethyl-6-{2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4(phenyl
amino) carbonyl}-1H- ·
Pyrrol-1-y}-ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate
98%(L-1) CIPROFLOXACIN ·
2,4 Dichlorofluoro benzene ·
2,4 Dichloro 5 -fluoroacetophenone ·
Cyclopropylamine ·
Dimethyl carbonate ·
2-(2,4-Dichloro-5-fluoro
benzoyl-3-cyclopropylamino-acrylic-methylester ( Acrylate ) ·
7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic
acid ( Q Acid ) CELECOXIB ·
4-Sulphonamido Phenyl Hydrazine Hydrochloride ( 4-SPH
HCL ) ·
1-(4 Methyl Phenyl)-4,4,4 Trifluorobutane-3-Dione
( Diketone ) ·
4 Methyl Acetophenone CLOPIDAGREL ·
2-Thiopheneethylamine ·
a-Bromo-2-chlorophenylacetic acid ·
L( - ) Camphor-sulfonic acid ·
2-Thiophene ethanol ·
DL-2Chlorophenylglycine DICLOFENAC SODIUM ·
2,6 Dichloro phenol ·
Ortho chloro phenol ·
Methyl Monochloro Acetate ·
Indolinone
·
1,3 Difluorobenzene FISINOPRIL ·
N-Benzoyl-trans-4-hydroxy-L-proline methyl ester ·
Trans-1-Cyclohexyl-L-Proline KETOCONAZOLE ·
2,4 Dichloroacetophenone ·
Imidazole ·
Acetyl Hydroxy Phenyl Piperazine ( AHPP ) ·
CIS Tosylate LOSARTAN ·
2-Cyano4-methyl biphenyl (OTBN) ·
2-Butyl-4(5)-chloro-5(4)-imidazole carboxaldehyde LORATIDINE ·
3(2-(3-Chloro phenyl)ethyl)-2-Cyano pyridine(
L-5) ·
3(2-(3-Chloro phenyl)ethyl)-2-Pyridine carboxylic
acid ( L-6) ·
8-Chloro 6,11 Di hydro 5-H-Benzo-{5,6}Cyclo hepta
1,2 pyridine-11-one(Keto Lorata) ·
8-Chloro-11(1-Methyl-4-Piperidyllidene5,11)Di
hydro-5-H-Benzo 5,6 Cyclo hepta 1,2 pyridin LISINOPRIL ·
N6-Trifluoroacetyl-L-lysine ·
N2-{(1S)-ethoxy
carbonyl-3-phenylpropyl}-N6-trifluoroacetyl-L-lysine ·
N2-{1S)-ethoxy
carbonyl-3-phenylpropyl}-N6-trifluoroacetyl-L-Lysyl-I-proline ·
Ethyl 2-oxo-4-phenyl butyrate METAPROLOL
SUCCINATE / TARTARATE ·
4-(2-Methoxyethyl )Phenol - 99.5% Min. ·
L (+) Tartaric acid MONTELUKAST
SODIUM ·
Cyclopropane dimethanol ·
2-{3S)-3{(1E)-2-(7-Chloro-2-Quinolinyl)Ethenyl}-3-Hydroxypropyl}-Benzoic
acid methyl ester ·
a-{3-{2-(7-Chloro-2-Quinolinyl)Ethenyl}Phenyl}-2-(1-Hydroxy-1-Methylethyl)-1,{2-(E)}-Benzenepropanol NAPROXEN ·
2-Acetyl-6-Methoxy naphthalene RAMIPRIL ·
(S,S)-2-azabicyclo{3,3,0}-octane-3-carboxylic
acid benzylester hydrochloride ·
(S,S,S )-2Azabicyclo{3,3,0}-octane-3-carboxylic
acid benzylester hydrochloride ·
N-{1-(S)-(Ethoxycarbonyl)-3-phenylpropyl}L-alanine
( ECPPA ) TERBINAFINE HCL ·
Trans-1-bromo-6,6-dimethyl-2-heptene-4-yne ·
Trans-1-Chloro-6,6-dimethyl-2-heptene-4-yne ·
N-Methyl-1-naphthylmethylamine HCL TICLOPIDINE ·
2 Thiophene ethanol ·
Orthochloro benzylamine NAPROXEN ·
6-Methyl-N,N-dimethyl-2-(4-methylphenyl)-2-hydroxyimidazo{1,2-a}pyridine-3-acetamide ·
6-Methyl-2-(4-methylphenyl)imidazo{1,2-a}pyridine ·
N,N-Dimethyl-2,2-dimethoxy acetamide ·
Zolpidic acid PHOSGINATION ·
Benzyl chloroformate - 50% in Toluene ·
Benzyl chloroformate - 90-95% ·
Thiophosgene ·
4 Chlorobutryl chloride |
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
State Bank of
India, Wagle Industrial Estate Branch, Road No. 22, Wagle Estate,, Thane - 400604, Maharashtra,
India |
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
D.A Oak and Company Chartered Accountants |
|
Address : |
Sudha Sadan, B.P.D Road, Vishnu Nagar, Naupada, Thane – 400602,
Maharashtra, India |
|
PAN.: |
AAAPO6133A |
CAPITAL STRUCTURE
As on 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2000000 |
Equity Shares |
Rs.10/- each |
Rs.20.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1500000 |
Equity Shares |
Rs.10/- each |
Rs.15.000
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
15.000 |
15.000 |
15.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
17.343 |
9.686 |
2.380 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
32.343 |
24.686 |
17.380 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
0.613 |
36.567 |
16.000 |
|
|
2] Unsecured Loans |
13.007 |
34.328 |
12.878 |
|
|
TOTAL BORROWING |
13.620 |
70.895 |
28.878 |
|
|
DEFERRED TAX LIABILITIES |
(0.193) |
(0.097) |
0.037 |
|
|
|
|
|
|
|
|
TOTAL |
45.770 |
95.484 |
46.295 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
3.118 |
2.320 |
0.802 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
30.961 |
30.961 |
22.761 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
2.882
|
6.687 |
13.487 |
|
|
Sundry Debtors |
65.001
|
27.654 |
33.658 |
|
|
Cash & Bank Balances |
9.644
|
38.670 |
7.473 |
|
|
Other Current Assets |
12.203
|
24.575 |
0.483 |
|
|
Loans & Advances |
7.643
|
3.574 |
2.614 |
|
Total
Current Assets |
97.373
|
101.160 |
57.715 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
75.329
|
27.570 |
29.416 |
|
|
Other Current Liabilities |
6.786
|
5.550 |
2.915 |
|
|
Provisions |
3.622
|
5.931 |
2.786 |
|
Total
Current Liabilities |
85.737
|
39.051 |
35.117 |
|
|
Net Current Assets |
11.636
|
62.109 |
22.598 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.055 |
0.094 |
0.134 |
|
|
|
|
|
|
|
|
TOTAL |
45.770 |
95.484 |
46.295 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
|
|
|
|
|
TURNOVER |
199.101 |
230.014 |
118.820 |
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
11.183 |
13.102 |
5.048 |
|
|
|
|
|
|
|
Less |
TAX |
3.526 |
4.393 |
1.824 |
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
7.657 |
8.709 |
3.224 |
|
|
|
|
|
|
|
|
TOTAL EARNINGS |
75.290 |
120.314 |
13.427 |
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
5.10 |
-- |
-- |
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
Return on Total Assets (PBT/Total Assets} |
(%) |
11.13
|
12.66 |
8.63 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.35
|
0.53 |
0.29 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
3.07
|
4.45 |
3.68 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.14
|
2.59 |
1.64 |
LOCAL AGENCY FURTHER INFORMATION
|
Check List by Info
Agents |
Available in Report
(Yes / No) |
|
1) Year of Establishment |
Yes |
|
2) Locality of the firm |
Yes |
|
3) Constitutions of the firm |
Yes |
|
4) Premises details |
No |
|
5) Type of Business |
Yes |
|
6) Line of Business• |
Yes |
|
7) Promoter’s background |
Yes |
|
8) No. of employees |
No |
|
9) Name of person contacted |
No |
|
10) Designation of contact person |
No |
|
11) Turnover of firm for last three years |
Yes |
|
12) Profitability for last three years |
Yes |
|
13) Reasons for variation <> 20% |
-- |
|
14) Estimation for coming financial year |
No |
|
15) Capital in the business |
Yes |
|
16) Details of sister concerns |
No |
|
17) Major suppliers |
No |
|
18) Major customers |
No |
|
19) Payments terms |
No |
|
20) Export / Import details (if applicable) |
No |
|
21) Market information |
-- |
|
22) Litigations that the firm / promoter |
-- |
|
23) Banking Details |
Yes |
|
24) Banking facility details |
Yes |
|
25) Conduct of the banking account |
-- |
|
26) Buyer visit details |
-- |
|
27) Financials, if provided |
Yes |
|
28) Incorporation details, if applicable |
Yes |
|
29) Last accounts filed at ROC |
Yes |
|
30) Major Shareholders, if available |
Yes |
Note:
The registered office address of the company has been shifted from “1802, Ixora Towers, Hiranandani Meadows, Gladys- Alwaris Road, Off Pokharan-2 Road, Thane - 400607, Maharashtra, India” to the present address w.e.f. 01.07.2010.
Operations Review
and Outlook
In spite of the global trends of recession, the Company has delivered
sustainable profits which emphasise on the fundamental strengths of the Company
and its dedicated personnel. The outlook remains positive and strong, for years
to come.
Bankers Charges
Report as per Registry
|
Corporate
identity number of the company |
U24239MH2007PTC173718 |
|
Name of the
company |
SYNERGY UNITED PHARMACHEM
PRIVATE LIMITED |
|
Address of the
registered office or of the principal place of business in |
G-1, Tiffany Building, Near Hiranandani Hospital, Hiranandani Estate,
Ghodbander Road, Thane – 400607, Maharashtra, India E-mail : accounts@synergyunited.in
|
|
This form is for |
Modification of charge |
|
Charge
identification (ID) number of the charge to be modified |
10093182 |
|
Type of charge |
Book debts Others (Plant and Machinery, Furniture and
Fixtures.) |
|
Particular of
charge holder |
State Bank of
India, Wagle Industrial Estate Branch, Road No. 22, Wagle Estate, Thane –
400604, Maharashtra, India E-mail : ku.manoj@sbi.co.in |
|
Nature of
instrument creating charge |
Supplemental
Agreement of loan cum hypothecation. |
|
Date of
instrument Creating the charge |
04.08.2010 |
|
Amount secured by
the charge |
Rs.92.000
Millions |
|
Brief of the principal
terms an conditions and extent and operation of the charge |
Rate of Interest Interest 2% above
SBAR (SBAR = 11.75% w.e.f. 29.06.2009). Present effective rate 13.75% p.a. Terms of
Repayment Repayable on
demand. Margin Raw Materials -
Imported - 25%, Raw Materials - Indigenous - 25%, Semi Finished Goods -
33.33%, Finished Goods - 25%, Components / Consumable / Spares - 25%,
Domestic Receivables (Cover Period 90 days) - 40%, Export Packing Credit -
10%, Letter of Credit (cash margin) - 25%. Extent and
Operation of the charge Security to cover
principal amount together with interest, costs, charges and expenses etc. Others EPD (Within
overall FB limit of Rs. 45.000 Millions) - (Rs. 35.000 Millions), EBD/EBN -
Rs. 45.000 Millions, DCC (Within overall FB limit of Rs. 45.000 Millions) -
(Rs. 5.000 Millions), LC (Import and Inland) - Rs. 45.000 Millions, Forward
Contract Limit of Rs. 100.000 Millions (notional indebtedness @ 2.00% of FC
limit) - Rs. 2.000 Millions, Total - Rs. 92.000 Millions. All other terms
and conditions as per the sanctioned letter and loan agreement. |
|
Short particulars
of the property or asset(s) charged (including complete address and location
of the property) |
Hypothecation of
Raw Materials, Semi Finished Goods, Finished Goods purchased out of bank
Finance. Hypothecation
charge on Sundry Debtors, export receivables including goods in transit
covered by document of title, letter of credit, security deposits and other
current assets of the Company. |
|
Particulars of
the present modification |
Now by this
present and modification an additional loan facility is granted to the
company so that the total loan amount is increase in Rs. 90.000 Millions to
Rs. 92.000 Millions |
Fixed Assets:
·
Computer
·
Electrical Installation and Fittings
·
Office Equipments
·
Vehicles
·
Furniture’s and Fixtures
Website Details:
Profile:
subject, is a professionally managed pharmaceutical, intermediates and
chemical services company, engaged into merchant exports, trading, providing
technical support, indenting, strategic sourcing and facilitating contract
manufacturing solutions.
To identify the needs of their customers and align them with reputed
international manufacturers of bulk drugs, intermediates, chemicals and speciality
products in India and international markets will remain their key objective.
Synergy United will provide focused customer service including marketing,
technical back up and sourcing solutions for international buyers, thereby
creating value and sustained growth opportunities for their esteemed customers.
They have a presence in every continent through their agents and
associates, thus assuring their clients prompt and first class services
regardless of the location of their business. Their network is built over three
decades and enjoys high level of confidence, mutual trust and good will. They
take pleasure in working collaboratively with all their associates and believe
in long term strong relationships with them. The company will also assist in sales
and distribution for their clients by stock and sale and proximity to markets
through the network of their associate companies all over the world.
They offer their clients reliable sources for key raw materials on a long
term basis. Their sources have been checked for their delivery capabilities,
reliability and quality over a few decades. On case by case basis, they are
also willing to assist in creating MOU with suppliers.
With a cumulative experience of over 100 years in API , intermediates
and chemical industry, the members of their organization have built themselves
a formidable reputation and share outstanding good will with end users. With
close proximity to the market, they can leverage our strengths to effectively
promote our client’s products and services.
Subject understands the importance of the technical expertise and total
quality management and shall always strive to incorporate these strengths into
their core competencies, offering more comprehensive solutions to their
alliances and associates. Synergy United Pharmachem is looking forward to
engaging into long term mutually beneficial business associations with members
of pharmaceutical and chemical industry and continues their pursuit to offer
the best value and services to their customers.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is or
was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.29 |
|
|
1 |
Rs.88.26 |
|
Euro |
1 |
Rs.70.82 |
INFORMATION DETAILS
|
Report Prepared
by : |
BSN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
46 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.